| Hans-Günter Meyer-Thompson | Buprenorphin
Injectable therapy blocks opioid euphoria, withdrawal symptoms in trial
A study led by investigators in the University of Kentucky Center on Drug and Alcohol Research (CDAR) has demonstrated a weekly injectable formulation of buprenorphine, CAM2038, suppresses symptoms of withdrawal in patients with opioid use disorder (OUD). (medicalxpress.com, 26.06.2017)
https://medicalxpress.com/news/2017-06-therapy-blocks-opioid-euphoria-symptoms.html